2026年11月4日星期三
M
Atlante Universale
Notizie flash globali
Singapore's Insignia Ventures backs rural Japan for Davos-inspired academy— 日经 Nikkei AsiaThe great yen rebalancing— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaNorth Korea leans on China and Russia to drive 3% economic growth— 日经 Nikkei AsiaJapan's IHI wins key role in Westinghouse's new Poland nuclear plant— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaSingapore's Insignia Ventures backs rural Japan for Davos-inspired academy— 日经 Nikkei AsiaThe great yen rebalancing— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaNorth Korea leans on China and Russia to drive 3% economic growth— 日经 Nikkei AsiaJapan's IHI wins key role in Westinghouse's new Poland nuclear plant— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

Fonte 柳叶刀 Lancet11 giorni fa
Sintesi del contenuto

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

Questo sito fornisce solo titoli e indici di riepilogo; il contenuto completo e i diritti d'autore appartengono all'editore originale. Clicca sul link all'articolo originale per leggerlo.

Vai all'articolo originale
Canale di appartenenza
Salute
Regione di appartenenza
Regno Unito
Lingua originale
English
Numero di voce
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Atlante Universale